|
|
Volumn 25, Issue 5, 2007, Pages 489-490
|
|
Despite glacial progress, US government signals support for personalized medicine
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ILOPERIDONE;
INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
RILONACEPT;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
VILAZODONE;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG RESEARCH;
DRUG RESPONSE;
FOOD AND DRUG ADMINISTRATION;
GOUT;
GOVERNMENT;
HEALTH CARE;
HEALTH SERVICE;
HUMAN;
NOTE;
PHARMACOGENOMICS;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SCHIZOPHRENIA;
UNITED STATES;
UNSPECIFIED SIDE EFFECT;
DELIVERY OF HEALTH CARE;
DRUG INDUSTRY;
GOVERNMENT AGENCIES;
GOVERNMENT REGULATION;
PHARMACOGENETICS;
UNITED STATES;
|
|
EID: 34249672339
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0507-489 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
